Talk:Qiagen

message: This reads like a carbon-copy of the corporate information. Should this be flagged for neutrality?128.32.3.26 01:55, 13 June 2006 (UTC)
thread_title: Untitled

message: I think it's time to bring back the advert flag -- the only information here seems to be from Qiagen's own marketing and investment materials, most of it goes unsourced, and all of it goes unchallenged. I'll try to spend some time here soon, but this article still needs a fair bit of clean-up. Mote (talk) 03:11, 26 November 2010 (UTC)
thread_title:  Advert flag 

message: I read the above comments about advertisement; I can't assess whether the article today in 2019 still has this problem, but what I consider distinctly missing is the history of how the company was started, e. g. who were the founders? Too much information is missing right now; and indeed some parts seem to focus too much on a product portfolio. I think it is ok to mention the products, but this must be in relation to other parts, in particular what people may expect from reading such an article. 2A02:8388:1604:CA80:ED23:10FB:E45B:E735 (talk) 13:10, 30 June 2019 (UTC)
thread_title:  History of the company 

message: * What I think should be changed (include citations):
First of all, I would like to make transparent that I'm working in QIAGEN's public relations department. As this implies a COI for this article, I suggest the changes I would like to make here instead of implementing them directly.
I would like to restore the "Acquisitions" section of QIAGEN's Wikipedia article after it had been deleted due to the lack of reliable sources. I have researched suitable sources that should match the Wikipedia guidelines. Please let me know if sources are not compliant with the guidelines so I can try to find alternatives.
I would like to add the following and have included the sources:
Acquisitions In 2004, QIAGEN acquired key assets of Molecular Staging, Inc. Two years later, QIAGEN established its Asia regional headquarters in Shanghai. In 2007 sales reached US$649.8 million and the number of employees surpassed 2,600. QIAGEN acquired Digene for US$1.6 billion, furthering QIAGEN in molecular diagnostics by revenue and diagnostics for disease prevention.
In 2009, QIAGEN began building its Personalized Healthcare business through the acquisition of DxS Ltd, in a deal valued at US$95 million and it acquired SABiosciences Corp. in a deal valued at US$90 million. At the end of 2009 QIAGEN surpassed the US$1 billion revenue mark and had over 3,500 employees. QIAGEN became one of the first companies to release a clinically verified diagnostic test for the detection of H1N1, more commonly known as Swine Flu.
In 2010, QIAGEN acquired ESE GmbH, giving the company access to point of need testing devices for the application of molecular diagnostic tests without laboratory infrastructure.
In 2011, QIAGEN acquired Ipsogen S.A. for US$101 million, adding to the company's product and IP portfolio in the blood cancer space. QIAGEN also acquired Cellestis Limited for US$374 million, giving the company access to QuantiFERON technology for disease detection and prevention. The company added two new offices in the Asia Pacific region in New Delhi, India and Taipei, Taiwan. The company announced a comprehensive restructuring program to focus on high-growth areas such as personalized medicine and business in emerging markets. The program includes workforce reduction and internal restructuring affecting approximately 10% of the company's 3,900 positions.
In 2013, QIAGEN acquired Ingenuity Systems. QIAGEN also acquired CLC bio, which offers bioinformatics analysis software. In 2015, QIAGEN acquired AdnaGen's circulating tumor cell enrichment technology. QIAGEN also acquired Enzymatic enzyme solutions.
In March 2015, a management buyout of QIAGEN Marseille led to the creation of HalioDx. In late 2015 the GeneReader NGS System was launched, and the acquisition of Mo Bio Laboratories was completed.
In 2016, QIAGEN acquired the Danish molecular diagnostics company Exiqon.
In 2017, QIAGEN acquired OmicSoft Corporation, a leading provider of highly curated public datasets.
In 2018, QIAGEN transferred its listing to New York Stock Exchange. In April 2018, QIAGEN acquired the Spanish firm STAT-Dx and launched the QIAstat-Dx molecular diagnostics platform.
In 2019, QIAGEN announced the acquisition of Formulatrix assets to develop a digital PCR platform. An additional acquisition of N-of-One, a privately held U.S. molecular decision support company and pioneer in clinical interpretation services for complex genomic data, to expand its QCI bioinformatics offerings. In October 2019 QIAGEN entered into an agreement with Illumina granting QIAGEN non-exclusive rights to develop and globally commercialize IVD kits to be used together with Illumina's diagnostic instruments.
In September 2020 QIAGEN announced the acquisition of Michigan-based NeuMoDx Inc. to market two fully integrated systems for automated PCR.
In May 2022, QIAGEN acquired the majority stake in BLIRT S.A., adding new R&D and manufacturing capabilities for customized and standardized recombinant enzymes, as well as molecular biology reagents.
In January 2023, the business announced its intention to acquire Verogen for $150 million. This deal included acquiring GEDmatch.
* Why it should be changed:
The acquisitions are an important part of QIAGEN's history and development and should therefore be part of the article.
Editorqiagen (talk) 14:26, 19 March 2024 (UTC)
thread_title:  Restoring "Acquisitions" section with suitable sources